Skip to main content
. 2023 Jul 4;33:210–226. doi: 10.1016/j.omtn.2023.06.023

Figure 3.

Figure 3

In vivo hepatic expression of hOTC proteins in mice treated with hOTC-mRNA/LNP

(A) Hepatic OTC enzymic activity in female BALB/c mice intravenously injected with hOTC-mRNA/LNP at 2.0 mg/kg. Liver samples were collected three days after the injection. Values are expressed as means ± SD with individual values. ∗p < 0.05 by Mann-Whitney U test. The dotted line shows the mean of the untreated group. Untreated, n = 4; treated, n = 4. (B) Immunohistochemical distribution of hOTC proteins in the liver of BALB/c mice intravenously injected with hOTC-mRNA/LNP at 1.0 or 2.5 mg/kg, or saline. Livers were harvested 24 h after the injection. hOTC was stained using anti-hOTC mouse monoclonal antibody with nuclear staining with DAPI. C, central vein; P, portal vein. Scale bar, 100 μm. (C) Immunohistochemical staining of hOTC and albumin for liver specimens of hOTC-mRNA/LNP-treated (2.5 mg/kg) and untreated BALB/c mice. The bottom images are hOTC-mRNA/LNP-administered mouse liver samples processed without (w/o) the primary antibodies (Ab). Scale bar, 20 μm. (D) Immunohistochemical staining of hOTC proteins and prohibitin, a mitochondria maker, in the liver specimens of BALB/c mice intravenously injected with hOTC-mRNA/LNP at 2.5 mg/kg or untreated mice. Scale bar, 10 μm. Hepatic specimens were collected 24 h after the injection (C and D).